Baysient Unveils Enhanced iDose® GEN7.0 for Precision Dosing in 16 Inflammatory Conditions Baysient has launched iDose® GEN7.0, a precision dosing platform now supporting 17 inflammatory diseases, improving treatment outcomes in various specialties.

Baysient Unveils Enhanced iDose® GEN7.0 for Precision Dosing in 16 Inflammatory Conditions #USA #Fort_Myers #precision_dosing #Baysient #iDose